Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2'-f-ara-deoxyuridine (FAU) is a synthetic nucleoside analog structurally related to deoxyuridine. It acts as a prodrug that is phosphorylated and methylated within cells, ultimately being incorporated into DNA as FMAUMP. This incorporation leads to inhibition of DNA synthesis and cell growth. The drug’s activation depends on the catalytic activity of thymidylate synthase (TS), making it particularly effective in tumors with high TS activity that are resistant to traditional TS inhibitors. FAU has been studied as an antitumor agent and suicide prodrug for targeting cancer cells by exploiting their elevated TS levels[1][3]. Its mechanism allows selective toxicity toward certain tumor types while potentially enabling noninvasive imaging of tumor TS activity using radiolabeled derivatives[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2'-f-ara-deoxyuridine.